The agreement will transfer late-stage development, clinical manufacturing, and commercial supply of the biosimilar from Ipca to BSS. Ipca will receive milestone fees for the knowhow and technology transfer, along with royalties on net sales once the product is commercialised. Shares of Ipca Laboratories Ltd ended at ₹1,350.60, down by ₹43.75 or 3.14%, on the BSE today, September 24.
